U.S. territories include the following: Guam, Puerto Rico, the U.S. Virgin Islands, American Samoa, Swains Island and the Commonwealth of the Northern Mariana Islands. If the traveler also visited non-U.S. territories, he/she is required to present a passport.
The Basics of Subordination, Nodisturbance and Attornment Agreements (SNDAs) Subordination, non-disturbance and attornment agreements (âSNDAsâ) are used to adjust the priorities between commercial tenants and lenders of the property they are leasing. In the absence of an SNDA, the priorities between tenants and lenders are governed by state recording acts and related common law principles. For the purpose of establishing the priority of competing liens against real estate, leases are viewed as liens.
Saxagliptin (rINN), previously identified as BMS-477118, is an oral hypoglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug. In June 2008, it was announced that Onglyza would be the trade name under which saxagliptin will be marketed.